Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia
Tyler A Berger,1 Matthew W Manry,1,2 Lucas B Lindsell,1,2 James M Osher,1,2 Daniel M Miller,1,2 Robert E Foster,1,2 Christopher D Riemann,1,2 Michael R Petersen,1,2 Robert A Sisk1– 3 1Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA; 2Cincinnati Eye Institute, Cin...
Saved in:
Main Authors: | Berger TA, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, Sisk RA |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b54a859aabc144b6b64c320b371c802d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Telangiectasia hemorrágica hereditaria: Tratamiento farmacológico
by: Molinos-Castro,Sonia, et al.
Published: (2009) -
Macular Dystrophy with Bilateral Macular Telangiectasia Related to the CYP2U1 Pathogenic Variant Assessed with Multimodal Imaging Including OCT-Angiography
by: Khaled El Matri, et al.
Published: (2021) -
Efecto de la vitamina E(DL alfa-tocoferol) sobre el daño cromosómico en linfocitos de pacientes con ataxia telangiectasia
by: Marcelain C,Katherine, et al.
Published: (2002) -
Telangiectasia hemorrágica hereditaria: Aspectos otorrinolaringologías
by: Alvo V,Andrés, et al.
Published: (2012) -
Trasplante hepático por insuficiencia cardíaca secundaria a telangiectasia hemorrágica hereditaria o enfermedad de Rendu Osler Weber. Caso clínico
by: Ahumada,Vanessa, et al.
Published: (2017)